Alexander Panossian
Overview
Explore the profile of Alexander Panossian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
879
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Panossian A, Lemerond T, Efferth T
Pharmaceuticals (Basel)
. 2025 Feb;
18(2).
PMID: 40006074
Long-lasting brain fatigue is a consequence of stroke or traumatic brain injury associated with emotional, psychological, and physical overload, distress in hypertension, atherosclerosis, viral infection, and aging-related chronic low-grade inflammatory...
2.
Panossian A, Lemerond T, Efferth T
Pharmaceuticals (Basel)
. 2024 Apr;
17(4).
PMID: 38675443
Background: Despite some evidence supporting the synergy concept, the commonly known assumption that combinations of several herbs in one formulation can have better efficacy due to additive or synergistic effects...
3.
Ratiani L, Pachkoria E, Mamageishvili N, Shengelia R, Hovhannisyan A, Panossian A
Pharmaceuticals (Basel)
. 2023 Sep;
16(9).
PMID: 37765004
. This study aimed to assess the efficacy of the treatment of Kan Jang, a fixed combination of (Burm. F.) Wall. ex. Nees and (Rupr. & Maxim.) Maxim extracts in...
4.
5.
Panossian A, Abdelfatah S, Efferth T
Pharmaceuticals (Basel)
. 2022 Nov;
15(11).
PMID: 36355517
Background: This study aimed to assess the effect of a fixed combination of Red Ginseng and Red Sage (RG-RS) on the gene expression of neuronal cells to evaluate the potential...
6.
Panossian A, Efferth T
Pharmaceuticals (Basel)
. 2022 Sep;
15(9).
PMID: 36145272
The reductionist concept, based on the ligand-receptor interaction, is not a suitable model for adaptogens, and herbal preparations affect multiple physiological functions, revealing polyvalent pharmacological activities, and are traditionally used...
7.
Ratiani L, Pachkoria E, Mamageishvili N, Shengelia R, Hovhannisyan A, Panossian A
Pharmaceuticals (Basel)
. 2022 Aug;
15(8).
PMID: 36015163
Kan Jang, the fixed combination of (Burm. F.) Wall. ex. Nees and (Rupr. & Maxim.) Maxim extracts, is a herbal medicinal product for relieving symptoms of upper respiratory tract infections....
8.
Karosanidze I, Kiladze U, Kirtadze N, Giorgadze M, Amashukeli N, Parulava N, et al.
Pharmaceuticals (Basel)
. 2022 Mar;
15(3).
PMID: 35337143
Currently, no effective treatment of comorbid complications or COVID-19 long-haulers during convalescence is known. This randomized, quadruple-blind, placebo-controlled trial aimed to assess the efficacy of adaptogens on the recovery of...
9.
Efferth T, Zacchino S, Panossian A
Phytomedicine
. 2021 Dec;
95:153896.
PMID: 34959124
No abstract available.
10.
Narimanyan M, Jamalyan K, Balyan A, Barth A, Palm S, Wikman G, et al.
J Tradit Complement Med
. 2021 Nov;
11(6):552-562.
PMID: 34765519
Background And Aim: and preparations and their fixed combination, called Kan Jang®, are traditionally used for relieving symptoms of upper-respiratory tract infections (URTIs). This study aimed to assess the efficacy...